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Background: Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency 
Syndrome (AIDS) is recognized as the chief cause of morbidity and mortality in Sub-Saharan 
Africa. South Africa is known to bear the highest number of people living with HIV globally, 
while KwaZulu-Natal is the worst affected province in this country. 
Aim: To identify the determinant of morbidity and mortality in the modern antiretroviral 
therapy (ART) era in South Africa. 
Study design: A cross-sectional study. To achieve the objective, a mixed data acquisition 
method was applied using qualitative and quantitative data. These included a systematic review 
and a retrospective chart review.  
Data collection and analysis: For the systematic review, relevant studies were searched from 
the following databases: Google Scholar, PubMed, CINAHL. Two review authors 
independently screened titles abstracts and full-text articles in duplicate, extract data and assess 
the bias. Discrepancies were resolved by discussion or arbitration of a third review author. The 
study used the Preferred Reporting Item of Systematic Review (PRISMA 2015) guideline.  
This study used R software version 3.6.2. to synthesis the data, graphic displays were used to 
visually compare the prevalence of comorbidities across the study region. 
With the retrospective chart review, we conducted a study of all patients admitted at King 
Edward medical wards, Durban, South Africa from January to December 2018. Data were 
obtained from medical records, including demographic profile, clinical attributes and 
laboratory records. Data were analysed using R software version 3.6.2. In addition, the 
association between the covariates was tested either with the Chi-Square test, Kruskal Wallis 
or Wilcoxon rank-sum test depending on the type of variables. A p-value < 0.05 was used as a 
benchmark for determining the level of statistical significance 
Results: For the systematic review a total of 409 articles were obtained from the database 
search, finally12 articles were eligible for data extraction. All 12 studies included were 
published between 2008 and 2018 in English and they were conducted in Sub-Saharan Africa. 
Among them, three were conducted in Nigeria, two were conducted in Uganda, three were 
conducted in South Africa, one in Gabon, one in Ethiopia, one in Ghana, and one in Burkina 
Faso. In most of the included studies, tuberculosis was the first commonest causes of 
hospitalization accounted for 40.7% followed by anaemia with 34.2% and toxoplasmosis with 
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29.3%. It was as well the first cause of death accounted for 44.3% followed by anaemia with 
30.2% and toxoplasmosis 27.5%. Contrary one study reported anaemia as the first causes of 
hospitalization and two studies reported each respectively wasting syndrome and meningitis as 
the first causes of death. 
With regards to the chart review, a total of 577 (50.6%) females and 564 (49.4%) males were 
included in the study. The mean age of all the participants was 39.6±12.2, 506 (44.3%) patients 
had CD4 less than 200 cells /mm3 and 273 (23.9%) had VL ˃ 1000 copies/ml. Male gender 
[OR 1.39(1.07-1.8) p=0.015], age [OR1.02(1.01-1.03) p˂ 0.001], CD4 <200 cells/mm3 [OR 
2.14(1.37-3.45) p=0.001], VL ˃ 1000 copies/ml [ OR 1.93(1.08-3.63) p=0.032]  were 
associated with mortality among HIV infected patients admitted in the cohort. Tuberculosis 
(TB) was the most common diagnosis on admission and the leading cause of death which 
accounted for 257 (22.5%) and 73 (24.3%) respectively, followed by kidney disease with 
83(7.2%) for admission and with 38(12.6) for death. Only 70% of patients had been reported 
to be on ART. Age, men gender, CD4 cell and viral load were associated with mortality. 
Association between CD4 cell count and viral load was found. 
Conclusion: Despite the recent improvement of modern antiretroviral treatment, HIV/AIDS 
still causes hospitalization and death among HIV infected patients. For the systematic review 
as well as for the chart review, tuberculosis was the commonest cause of hospitalization and 
death in Sub-Saharan Africa and South Africa, but it was always followed by other 
opportunistic infection and other non-AIDS related conditions.  
There is a need to prevent opportunistic infection (especially tuberculosis) and to tackle the 
non-communicable disease related to HIV infection. Also, a need to start antiretroviral 
treatment early for patients living with HIV.  
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OVERVIEW OF THE THESIS 
 
Chapter 1: Introduction: Containing the background, the problem statement, the research 
questions, the aim and objectives, the literature review and the methodology. 
Chapter 2: The systematic review:  The manuscript is presented in the form of a journal 
article entitled ‘morbidity and mortality in the ART era in Sub-Saharan Africa: a systematic 
review’. 
Chapter 3: The retrospective chart review: the chapter is presented in the form of a 
manuscript entitled: morbidity and mortality in the modern ART era in a tertiary teaching 
hospital in South African, Durban.  

















CHAPTER 1: INTRODUCTION 
  
1.1 BACKGROUND 
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) 
remain one of the major global public health problems and cause substantial morbidity, 
mortality, negative socio-economic impact, and human suffering (1,2). Approximately 36.9 
million persons in the world lived with HIV infection in 2017 and 1.8 million persons were 
newly infected in the same year (3). Nearly 940,000 persons died from AIDS-related illnesses 
in 2017(3).  
Sub-Saharan Africa is one of the regions which is the most affected by HIV (4). The region 
contributes 68% of all HIV and/or AIDS patients in the world, while North America and Latin 
America has 4% each, Eastern Europe and Central Asia has 4% each and South-East Asia has 
12% (2). UNAIDS (2018) reported that 300,000 men and 270,000 women died of AIDS-related 
illness in Sub-Saharan Africa in 2017 (5). 
South Africa has the largest number of infected human immunodeficiency virus and the largest 
antiretroviral treatment program in the world (6). The prevalence of HIV has been increasing 
since 1990 in South Africa (7). In 2016 the national program of HIV in South Africa reached 
56% of all human immunodeficiency virus-infected with 3.8 million adults on treatment (8). 
The Joint United Nations Programme on HIV/AIDS (UNAIDS) policy was implemented in 
South Africa in September 2016 (9). In the same year, the country implemented universal ART 
eligibility and extending it to all 7.1 million HIV-positive South Africans (9). 
The country adopted also the World Health Organization (WHO) “test and treat” approach 
(10). 
Despite the widespread antiretroviral therapy availability in South Africa, little is known about 
the impact of its programme on adult HIV related hospitalization and results at the level of 
public sector hospital (11). 
The aim of the study was to identify the determinants of morbidity and mortality in the modern 
antiretroviral treatment (ART) era of patients of 12 years old or older admitted at King-Edward 






1.2 PROBLEM STATEMENT 
 
The antiretroviral therapy (ART) has led to a profound decrease in the morbidity and mortality 
among people living with AIDS (12, 13). However, despite the availability of ART, a 
substantial proportion of HIV infected patients has continued to die from both AIDS-related 
and non-AIDS-related causes (14). 
 
Studies found that several factors may contribute to these deaths, but the mortality rate, cause 
of death, and risk factors for death differs between countries and depending on factors such as 
cultural, socio-economic, healthcare and political issues (15, 16). 
In low and middle-income countries, disproportionately high mortality has been observed in 
the first few months after ART initiation, especially among profoundly immunosuppressed 
patients (16, 17). High-income countries showed decreases in death due to HIV, however, it 
was not the same as in low and middle-income countries (14, 18). 
Therefore, the study investigated the reason for hospitalization and causes of death in the 
modern antiretroviral treatment (ART) era at King-Edward hospital, a tertiary teaching hospital 
in Durban, KwaZulu-Natal from January to December 2018. 
 
1.3 RESEARCH QUESTIONS 
 
Main research question 
What are the determinants of morbidity and mortality in the modern antiretroviral treatment 
(ART) era in South Africa? 
Specific research question 
1. What are the research gaps on morbidity and mortality in the modern antiretroviral treatment 
(ART) era in Sub-Saharan Africa? 
2. What are the reasons for admissions in the modern antiretroviral treatment (ART) era in a 
tertiary teaching hospital in South Africa? 
3. What are the causes of death in the modern antiretroviral treatment (ART) era in a tertiary 





1.4 AIMS AND OBJECTIVES OF THE STUDY 
 
Main Aim 
To identify the determinants of morbidity and mortality in the modern antiretroviral treatment 
(ART) era in South Africa. 
Objectives 
1. To conduct a systematic review to identify the literature available or the research gaps 
on the morbidity and mortality in the antiretroviral treatment (ART) era in Sub-Saharan 
Africa.  
 
      2. To conduct a retrospective chart review focusing on the following issues:  
a)  Reasons for admissions in the modern antiretroviral treatment (ART) era at King-
Edward hospital in South Africa. 
b)  Causes of death in the modern antiretroviral treatment (ART) era at King-Edward 
hospital in South Africa. 
 
1.5 LITERATURE REVIEW 
 
In this Review the following sections are discussed: 
1. HIV/AIDS Globally 
2. HIV/AIDS in Sub-Saharan Africa. 
3. HIV/AIDS in South Africa. 
4. HIV/AIDS in KwaZulu-Natal. 
5. HIV/AIDS Policy. 
6.Morbidity and Mortality 
 
1.5.1 HIV/AIDS GLOBALLY 
Globally, the number of people infected with HIV has increased, statistics showed that 4.1 
million people were newly infected by HIV and 2.8 million died from AIDS-related to HIV in 
2005(19). According to Kelly (2000), AIDS is associated with the most deaths than another 
infectious disease in the world (20). The United Nations Joint Programme on HIV /AIDS 
estimated that 33 to 46 million people were infected worldwide in 2005(21). In lower-middle-
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income countries, HIV/AIDS is still an ongoing problem and still causes high morbidity and 
mortality (22). Almost 78 million people have been infected with HIV since its discovery in 
1981 (22) and as of today it has so far caused more than 34 million deaths (23). Eastern and 
Southern Africa with an estimated of 19 million people living with HIV and 960 000 new 
infections in 2015 remain the most affected region despite a global decrease in AIDS-related 
death and improvement of access to antiretroviral therapy worldwide (24). Data on reasons for 
hospitalization among children and adults with HIV globally as summarized by a systematic 
review identified tuberculosis and bacterial infections as the two most common causes of 
children and adults’ HIV admissions in all geographical regions and the most common causes 
of death (25). United Nations Member States aimed to reduce TB deaths among people living 
with HIV by 75% by 2020 (92). In 2017 five low- or middle-income countries, India (84%), 
Eritrea (83%), Djibouti (78%), Malawi (78%) and Togo (75%), achieved or exceeded the target 
of a 75 % reduction in TB deaths among people living with HIV (93).  
 
1.5.2. HIV/AIDS IN SUB-SAHARAN AFRICA 
 
Sub-Saharan Africa has been reported as the region hardest hit by HIV and AIDS in the world. 
The Southern African Development Community (SADC) countries are generally the hardest 
hit by HIV and AIDS (26). Different factors had been identified by different authors as reasons 
why the African population is more susceptible to HIV and AIDS in the world. Concurrent or 
simultaneous sexual intercourse practices by African men is argued as a major role player in 
the vast spread of HIV in Sub-Saharan African countries as opposed to developed countries 
characterized by serial monogamy practices (27). Other authors argued that political instability, 
underdevelopment, widespread poverty and poor infrastructure are the major reasons for the 
rapid spread of HIV in African countries (28). 
The 2009 AIDS epidemic update claimed that HIV and AIDS still have an enormous negative 
impact on business, households, communities and national economies in Sub-Saharan Africa. 
Sub-Sahara Africa has the biggest share of the 40 million people currently living with HIV and 
AIDS in the world (29, 28). In 2014 studies reported that Sub-Saharan Africa was the most 
affected region, 25.8 (24.0-28.7) million people were estimated living with HIV, the region 
accounted for nearly 70% of new infections worldwide (30). UNAIDS (2018) reported that 
300.000 men and 270.000 women died of AIDS-related illnesses in Sub-Saharan Africa in 
2017 (31).  Cryptococcal meningitis is one of the common and often cause of death among 
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HIV patients in Sub-Saharan Africa.  Some studies from Africa reported that 10% to 20% of 
deaths among HIV infected patients are attributable to cryptococcal meningitis (87, 88). 
The global burden of cryptococcal meningitis has been recently re-estimated at 223,100 cases 
(162,500 cases in sub-Saharan Africa) leading to 181,100 annual deaths (135,900 deaths in 
Sub-Saharan Africa).The highest annual incidence of cryptococcal meningitis has been found 
in Nigeria (27,100 cases), South Africa (21,400 cases), Mozambique (18,600 cases), India 
(18,300 cases), Uganda (12,200 cases), Ethiopia (9600 cases), Kenya (9000 cases) and Zambia 
(5000 cases) (89). Tuberculosis also remains the leading cause of death among people living 
with HIV, causing one in three AIDS-related deaths. In ART services in Sub-Saharan Africa 
the proportion of patients with tuberculosis is extremely variable, ranging between 5% and 
40% (90,91). Anaemia is the most common haematological manifestation of HIV disease and 
is frequent among HIV patients on antiretroviral therapy (ART) in Sub-Saharan Africa, with a 
prevalence ranging from 45- 87% (94). Among HIV infected patients, chronic kidney disease 
(CKD) has been observed as one of the main complications, with a prevalence ranging from 
3.5 to 48.5% in Sub-Saharan Africa (95). 
 
1.5.3. HIV/AIDS IN SOUTH AFRICA 
 
In South Africa, the first case of AIDS was diagnosed in 1982. Since then the prevalence has 
increased from less than one per cent in 1990 to nearly 25 per cent in 2000 (19). In 2005, 
statistics showed that 5.5 million South Africans were living with HIV and therefore South 
Africa was claimed to be the most affected country in the world (19). Since the beginning of 
the epidemic, it is estimated that 1.8 million people have died of AIDS-related diseases in the 
country (32). From 1997 to 2005 at least 40% of all deaths were related to AIDS (32) and 
consequently rising death have contributed to the decline in the country’s population growth 
rate from 1.25% in 2001 to 2002 to slightly more than 1% in 2005 to 2006 (32). The national 
household survey of 2005 showed young people aged between 15-24 years old as the most 
infected by HIV (34). South Africa launched the public-sector ART programme in 2004 (35). 
South Africa is identified as the largest HIV epidemic worldwide with an estimated 6.4 million 
people infected by HIV infection in 2012 (33). 
Over the past decade, there has been an unprecedented scaling-up of the programme with more 
than 2.6 million people having been initiated on antiretroviral therapy (36, 37). Estimation of 
3736 public health facilities across South Africa now offers free antiretroviral therapy to people 
(38). It has been shown that HIV mortality has decreased, and life expectancy has increased to 
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approximately 80% of normal life expectancy (39). The triple-drug antiretroviral therapy 
became available in the mid-1990s and heralded dramatic decreases in AIDS-defining diseases 
and hospital admissions for HIV related opportunistic infections in high-income economies 
countries (40, 41). 
With the prioritization of widespread ART availability, HIV /AIDS accounted for 
approximately 50% of medical ward admissions in public sector hospitals in South Africa (42). 
An estimation of 2.2 million deaths has been averted in South Africa in 2016 (43). 
According to the UNAIDS (2018), in 2017 in South Africa there were 7.2 million people living 
with HIV, among them 18.8% were aged between 15-49 years, 270,000 new HIV infections 
and 110,000 AIDS-related deaths (44). Sixty-one per cent of adults and 58% of children were 
receiving antiretroviral therapy treatment (44). 
 
Different factors have contributed to the increase in HIV infections in South Africa. These 
include; women’s vulnerability, lack of information and economic conditions.  The lack of 
viable economic conditions and poverty in rural and isolated areas influence men and women 
to migrate and look for employment and better economic opportunities. When men and women 
are away from their homes for a long period, this increases the risk of HIV infection (45). 
According to the world health organization, South Africa is one of 22 high tuberculosis (TB) 
burden countries, with a tuberculosis incidence rate of 520 per 100,00 population in 2015 (96). 
A study conducted in South Africa between 2011 and 2015, in total there were 2,377,676 
recorded deaths, approximately 14% (188,230) of individuals aged 15 to 64 years were reported 
to die due to tuberculosis (97).  Cryptococcal meningitis (CCM) continues to have significant 
mortality among HIV infected patients with low CD4 count, ranking between 30% and 50% 
(98). Approximately 95 of HIV-infected patients developpe anaemia during their disease (99). 
The cause of anaemia in HIV-infected patients is often multifactorial (100). 
1.5.4. HIV/AIDS IN KWAZULU-NATAL 
 
KwaZulu-Natal is estimated to have the highest prevalence of HIV infections in all provinces 
in South Africa (46). More than 55% of all South Africans infected with HIV are said to be 
living in KwaZulu-Natal and Gauteng provinces (47). Taylor et.al. (2002) argued that the high 
rate of HIV infection reported in younger women between 15-29 years suggested that many 
had been infected during their teens (46). They stipulated that the epidemic is mature, and 
deaths outstrip births in KwaZulu-Natal (46). Human Immunodeficiency Virus (HIV) 
prevalence among pregnant women is highest in KwaZulu-Natal and lowest in the Northern 
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Cape (48). Since the first antenatal HIV prevalence survey in 1990, KwaZulu-Natal has 
remained the centre with the highest prevalence of HIV (48). The prevalence rate of antenatal 
HIV in KZN as reported in 1990 was twice the national level and approximately ten per cent 
of the national average (48). A statement from the national department of health in South Africa 
reported that 47% of women who attended antenatal clinics tested positive for HIV infection 
in the Amajuba district and in the rural village of Umkhanyakude in the north, 51% of women 
aged 25 to 29 years old who had participated in the HIV survey also tested positive (47). 
UNAIDS (2007) reported that in keeping with current trends and no effective preventive 
programmes, an estimation of two-thirds of 15-year olds in this district could be infected with 
HIV by the time they reach their 35th birthday (32). The numbers of just over 1.5 million people 
infected with HIV and 115483 deaths related to HIV/AIDS in 2008 placed KwaZulu-Natal as 
the uppermost HIV infection prevalent province of South Africa (49). 
Some of the factors that make KwaZulu-Natal to have a high prevalence of HIV infection are; 
the lowest fraction of medical male circumcision, socioeconomic status, and education among 
others (50). In 2017, Statistics revealed that South Africa had a prevalence of HIV infection of 
18.9% in the general population, while it was almost 12.2% in KwaZulu-Natal (44). This 
province is distinguished for being the worst HIV infected Sub-region in the world with a very 
high prevalence within certain parts of it (51). 
 
1.5.5. HIV/AIDS POLICY 
 
a.  Global and Regional policy 
Many international policies and guidelines on HIV and AIDS had been developed by the Joint 
United Nations Programme for HIV and AIDS (UNAIDS) and many nations adopted them in 
their respective countries (52). The policies include the following issues: HIV prevention and 
treatment; orphans and vulnerable children; gender and HIV; prevention of mother to child 
transmission (PMTCT); orphans and vulnerable children; testing and counselling; women and 
girl (52). Southern African Development Community (SADC) countries, in the year 2000 
issued a policy entitled “managing the impact of HIV and AIDS in SADC” (53). The policy 
used a multi-sectoral approach and provided a strategic framework to tackle the HIV and AIDS 
epidemic in the region. The development of the framework aimed to achieve the SADC HIV 
and AIDS overarching goal which was: “to decrease the number of HIV and AIDS infected 
and affected individuals and families in the SADC region so that HIV and AIDS is no longer 
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a threat to public health and to the socio-economic development of member states” (53). To 
reach this goal, four main objectives must be followed: 
1. Reducing and preventing the incidence of HIV infection among the most vulnerable 
groups in the region. 
2.  Mitigating the socio-economic impact of HIV and AIDS. 
3. Reviewing, developing and harmonising policies and regarding prevention and control 
of HIV and AIDS transmission. 
4. Mobilizing and coordinating resources for the HIV and AIDS multi-sectoral response 
in the region (53). 
 
Among main actors in the HIV and AIDS response in the region, the policy recognised 
governments, Non-Governmental Organisations (NGOs) and the private sector (53). 
South Africa participated in the formulation of these global and regional policies, adopted and 
adapted them within its national context, like most of the countries. 
 
b. South Africa National Policy 
 
South Africa has formulated many policies and legislative acts since its attainment of 
democracy which aim to tackle HIV and AIDS epidemic. During the first decade of reaching 
democracy, the policies were well documented but there was a poor response of the government 
against HIV and AID epidemic (54, 55, 56). On the other hand, Government and civil society 
demonstrate more collaboration than before in the recent policies (57). 
 
             b.1. Policies concerning women 
 
The national department of health in 2008 released a document on the policy and guidelines. 
This document was for the implementation of the prevention of mother to child transmission 
(PMTCT) Programme to provide an update on the approach to the implementation of the 
PMTCT programme (58). The updated policy issued the following four stages of the PMTCT. 
Firstly, primary prevention of HIV especially among women of childbearing age; secondly, 
preventing unintended pregnancies among women living with HIV, thirdly, preventing HIV 
transmission from a woman living with HIV to her infant, and lastly, providing appropriate 




Among these four goals of international basic recommendations, South Africa prioritises the 
primary prevention of HIV among women living with their children and families. The policy 
notices that the involvement of civil society in the implementation programme is very 
important (58). 
Dual therapy with Nevirapine and AZT was introduced for PMTCT in July 2008 (59). 
The department of health and the South African national AIDS Council issued guidelines on 
the management of PMTCT in 2010 entitled clinical guidelines: prevention of mother to child 
transmission (PMTCT) (60).The old policy stated that pregnant women tested HIV positive 
with CD4 count less than 200 cells/μl had access to antiretroviral therapy whilst in the new 
policy all pregnant HIV positive women with CD4 count of 350 cells/μl or presented symptoms 
regardless of CD4 count were eligible for treatment, this policy became applicable on 1st April 
2010 (61). The policy also stipulates that all other positive pregnant women with CD4 count 
greater than 350 cells/μl are now eligible for treatment at 14 weeks of pregnancy to protect the 
baby instead of the last term of pregnancy as it was mentioned in the old policy (61). 
 
              b. 2. Policies concerning Men 
 
The policy suggests that men should actively participate in fighting AIDS through workshops 
and campaigns (62). It extends voluntary counselling and testing (VCT) to men (58).  
It also contains promotion of HIV and AIDS awareness, prevention and treatment among men 
living at high risk of HIV infection (63, 64) for example long distant truck drivers and men 
who have sex with men.  It suggests the distribution of condoms at truck stops and toll plaza, 
provision of treatment and VCT at strategic points (63, 64). 
Medical male circumcision helps to prevent HIV infection and the high prevalence of the 
epidemic in South Africa and it is suggested to be outlined in national policy (65). 
 
            b. 3. Antiretroviral therapy in South Africa 
Access to antiretroviral treatment (ART) is known for improving the quality of life for infected 
individuals, reducing opportunistic infections and AIDS-related mortality (66). 
South Africa’s antiretroviral therapy guidelines are based on the World Health Organization 
(WHO) guidelines which include three treatment regimens: 
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1. The first line regimen includes two nucleoside reverse transcriptase enzyme inhibitors 
(NRTI) with a non-nucleoside reverse transcriptase enzyme inhibitor (NNRTI) 
2. The second line regimen includes two NRTI’S with a protease enzyme inhibitor (PI) 
(67, 68). 
3. For the third line regimen, the following drugs are available for use: InSTIs (integrase 
strand transfer inhibitor) [DTG (dolutegravir) and RAL (raltegravir)], the newer PI 
DRV (protease inhibitor darunavir) and newer NNRTIs [ETR (etravirine) and RPV 
(rilpivirine)]. Note that regimen choice is individualised, and expert treatment provider 
is always consulted before using it. World health organization recommend TLD 
(Tenofovir, Lamivudine and Dolutegravir) for the first-line treatment of HIV and also 
in second line treatment (69, 70). 
Among the nucleoside reverse transcriptase enzyme inhibitors (NRTI), stavudine (D4T) was 
the most widely used in the first line in 2004 (71, 68) however, it was involved in causing 
peripheral neuropathy, hyperlactatemia and lipodystrophy (72, 73). Tenofovir replaced D4T as 
the nucleoside reverse transcriptase enzyme inhibitors (NRTI) in first-line treatment in April 
2010 (74, 75). By mid-2011, all HIV infected patients eligible for antiretroviral therapy 
coverage amounted to nearly 80% (76). In 2010 and 2011 the number of patients living with 
HIV who started antiretroviral therapy was in excess of the number of people who became 
eligible to take antiretroviral therapy over the same period and that exceeding the targets set in 
the 2007-2011 National Strategic Plan (NSP) (76). The number of HIV infected people who 
have access to antiretroviral therapy in South Africa increased to 31.2% in 2012 while in 2008 
it was 16.6 % (77).In the guidelines, the other overwhelming modification over the years has 
been the CD4 count threshold for starting of antiretroviral therapy (ART) (68). Initially, in 
2004, it was set at CD4 cell count < 200 cells/μl (68), and after 2013 it was increased to a CD4 
count of ≤ 350 cells/μl (75). As antiretroviral therapy was given to patient with CD4 < 500 
cells/μl, death, disability and expenditure on HIV/AIDS would decrease significantly over the 
40 years, and an assumption based on a well-run antiretroviral programme would appear (78). 
Therefore, South Africa took the decision to adopt this policy and expand its antiretroviral 
therapy programme to include patients with a CD4 count of ≤ 500 cells/μl in 2015 (79). 
South Africa adopted the WHO guidelines in September 2016 to initiate all HIV infected 
individuals on antiretroviral regardless of CD4 count (80). 
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The country implemented ‘test and treat’; if you are tested positive HIV you may access (ART) 
irrespective of CD4 count (81, 82).With that strategy South African antiretroviral therapy 
programme is trying to achieve targets set by Joint United Nation Programme on HIV/AIDS, 
to have 90% of all people tested for HIV, 90% treated and 90% virologically suppressed by 
2020 (80).According to UNAIDS (2018), 4.4 million people were receiving treatment in South 
Africa (83), which equates to 61% of people living with HIV in the country (83). 
South Africa has been reported to have the largest ART programme in the World (83). 
 
In recent years South Africa’s antiretroviral therapy services have expanded in keeping up with 
the WHO changing guidelines (81, 82).It was anticipated initially that the dramatic scale-up of 
ART would result in clinics and services becoming over-stretched and have a negative quality 
of care, however, after one-year, studies have shown that there was no significant effect on 
patients results related to the increase in antiretroviral therapy provision, either in terms of 
either morbidity or mortality (84).However, studies found that men were more likely to start 
antiretroviral therapy at an older age and later stage of infection and had almost double the 
mortality rate than that of women, which need to engage men in testing services and ensure 
that they are linked to treatment (84). Studies found also a decrease in mortality in the first year 
of antiretroviral therapy treatment initiation (85).  
 
1.5.6. MORBIDITY AND MORTALITY 
Morbidity and mortality are two measures commonly used for epidemiological surveillance, 
they describe the progression and severity of a given health event. Morbidity is the state of 
being symptomatic or unhealthy for a disease or condition, usually represented by prevalence 
or incidence. Mortality on the other hand, is related to the number of deaths caused the health 
event under investigation, communicated as rate or as an absolute number. Morbidity and 
mortality are two types of retrospective information that allows for continuous evaluation of 
the efficacy of either a specific health care system or an implemented intervention on place. 
(86). 
 1.6 METHODOLOGY 
 
1.6.1. Study design 
To achieve objectives, mixed data acquisition methods were applied using 




The study was carried out in two steps as follows: 
Step 1: conducted a systematic review to identify the literature reporting on 




. Studies reporting morbidity and mortality of HIV infected patients during 
the antiretroviral therapy (ART) era in Sub-Saharan Africa. 
. Studies published from 2008 to 2018. 
. Studies reporting on males or females ≥ 18 years old HIV infected. 
. Peer-reviewed English language publications. 
. Observational studies on Sub-Saharan Africa only. 
 
Exclusion Criteria: 
. Studies from outside Sub-Saharan Africa 
. Non-English literature 
. Patients < 18 years old 
. Studies reporting on morbidity or mortality in HIV-uninfected patients 
 
Data Electronic Search: 
 
We made use of the following databases: Google Scholar, PubMed, and 
CINAHL. The search strategy was based on a combination of relevant terms 
 
Data collection and analysis 
Two reviewers followed the inclusion criteria for selecting studies, they 
screened articles by their titles and abstracts eligibility. The full texts of 
articles were retrieved. The process of literature selection and reasons for 
exclusion and inclusion was documented by a PRISMA (Preferred Reporting 






Data extraction and management 
Data were extracted in accordance with the methods outlined in the 
Cochrane Handbook for the systematic review of interventions and the data 
extraction. Disagreements between the two review authors were resolved 
through discussion and by consulting a third author. R software was used for 
data synthesis. 
                          Step 2: conducted a retrospective chart review focusing on: 
• Reasons for admissions in the modern antiretroviral treatment (ART) 
era in a tertiary teaching hospital in South Africa. 
• Causes of death in the modern antiretroviral treatment (ART) era in a 
tertiary teaching hospital in South Africa. 
Inclusion criteria: 
• Medical records of HIV infected patients admitted at King Edward 
VIII Hospital in Durban, South Africa from January to December 
2018. 
• Males or females ≥ 12 years old HIV with HIV infection. 
• Pregnant females admitted to the medical wards at King Edward 
Hospital HIV infected 
 
Exclusion Criteria: 
• Patients   ≥ 12 years old non-HIV infected. 
 
1.6.2. Data Collection and Analysis: 
Data were collected from the clinical records of HIV infected patients 
admitted at King Edward VIII hospital. 
The Data collected, including age, gender, clinical parameters, history of co-
morbidities (tuberculosis, candidiasis, hepatitis c, toxoplasmosis, Kaposi’s 
sarcoma, Pneumocystis carinii etc.), laboratory data (HIV test, CD4 cell 
count, HIV RNA load), the reason of admissions and causes of deaths. 
R software was used for analysing data. Analytical statistics including 
percentage and frequency were described. Categorical data were presented as 
tables and graphs. Prevalence of morbidity and mortality were reported as a 
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percentage with 95 % confidence intervals. A p-value of <0.05 represented 
statistical significance. 
 
1.7 ETHICAL CONSIDERATIONS 
 
Permission: Ethical clearance for the study was obtained from the University of KwaZulu-
Natal Biomedical Research Ethics Committee (BREC), reference number BE345/19. We 
obtained also permission from King Edward hospital and the department of internal medicine. 
The risk to participants:  this study consisted of a systematic review and a retrospective chart 
review. Therefore, it did not pose any physical, biological or emotional risk to participants. 
Benefits: to identify gaps in research and to generate a hypothesis for a prospective study and 
to identify the determinants of morbidity and mortality in the modern antiretroviral treatment 
(ART) era in South Africa. 
Confidentiality: we did not disclose patient identification details. 
Consent: none needed because there was no interaction with patients. 
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CHAPTER 2: A SYSTEMATIC REVIEW 
 
Chapter 1 presented the background, aim, objectives, research question, the literature review 
and the methodology followed in this study. Chapter 2 responds to objective 1 of this study 
viz, to conduct a systematic review to identify the research gaps and the literature available on 
the morbidity and mortality in the ART era in Sub-Saharan Africa. The chapter is presented in 
the form of a manuscript entitled ‘morbidity and mortality in the ART era in Sub-Saharan 
Africa: a systematic review’. This manuscript and protocol will be submitted for review at the 
BMC: systematic review-journal. 
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Background: Worldwide despite the availability of antiretroviral therapy (ART), Human 
Immunodeficiency Virus (HIV)/ Acquired immunodeficiency syndrome (AIDS) still causes 
morbidity and mortality among patients. The aim of this study was to establish the causes of 
morbidity and mortality in the modern ART era in Sub-Saharan Africa. 
 
Method/design: We searched relevant studies from the following databases: Google Scholar, 
PubMed, CINAHL. Two review authors independently screened titles, abstracts and full-text 
articles in duplicate, extracted data and assessed bias. Inclusion criteria was based on studies 
reporting morbidity and mortality of HIV infected patients during the antiretroviral therapy 
(ART) era in Sub-Saharan Africa, studies published from 2008 to 2018, on males or females ≥ 
18 years old HIV infected, Peer-reviewed English language publications. Discrepancies were 
resolved by discussion or arbitration of a third review author. The study used the Preferred 
Reporting Item of Systematic Review (PRISMA 2015) guideline. 
 
Results: A total of 409 articles were obtained from the database search, finally12 articles met 
the inclusion criteria and were eligible for data extraction. Among them, three were conducted 
in Nigeria, two were conducted in Uganda, three were conducted in South Africa, one in 
Gabon, one in Ethiopia, one in Ghana, and one in Burkina Faso. In most of the included studies, 
tuberculosis was the leading cause of hospitalization and death, except in one which reported 
anaemia as the leading cause of hospitalization and in two which reported each respectively 
wasting syndrome and meningitis as the leading causes of death.  
 
Conclusions: Tuberculosis is the commonest cause of hospitalization and death in Sub-
Saharan Africa, but it is always followed by other infectious disease and other non-AIDS 
related causes. 
Systematic review registration: CDR42019141933 








Worldwide, despite the availability of antiretroviral therapy (ART), Human Immunodeficiency 
Virus (HIV)/ Acquired Immunodeficiency Syndrome (AIDS) still causes morbidity and 
mortality among patients. Since the first outbreak of HIV in 1981, 39 million people have died 
due to HIV and related diseases (1) 
In Sub-Saharan Africa, HIV/AIDS is a major public health concern. In 2009, 70% of the 33 
million people estimated to be infected by HIV, lived in Sub Saharan Africa (2). This region is 
the most affected by HIV/AIDS, 68% of the world’s infected patients live there (3). According 
to WHO 2013, 74% of HIV related deaths is in Sub-Saharan Africa (4). In 2014 studies reported 
that 25.8 million people were estimated to be living with HIV (9). 
According to UNAIDS (2018), Sub-Saharan Africa, particularly Eastern and Southern Africa 
remains the region most affected by the HIV epidemic accounting for 45% of the world’s HIV 
infections and 53% of people living with HIV globally (5). In this region in 2017, 19.6 million 
of adults and children were living with HIV, 800,000 of adults and children were newly 
infected with HIV and 380,000 of adults and children died due to AIDS (5). In the same year 
in Western and Central Africa 6.1 million of adults and children were living with HIV, with 
370,000 adults and children newly infected with HIV, and 280,000 adults and children dying 
due to AIDS (5). 
Antiretroviral therapy has improved the life expectancy of patients living with HIV/AIDS (6). 
Maximal and durable suppression of viral replication, restoration of immunologic function, 
reduction of HIV-related morbidity and mortality, improvement of quality of life, and 
prolonging survival are the major goals of ART (7). 
The fast growth in ART coverage represents one of the great public health success stories in 
the recent history of HIV care that lead to reduction of mortality and improvement of quality 
of life of people living with HIV/AIDS (PLWHA) (7). However, despite the availability of 
antiretroviral therapy (ART), a substantial portion of HIV infected patients have continued to 
be hospitalised and die from both AIDS-related and non- AIDS-related causes (8) 
This study is therefore aimed at identifying the determinants of morbidity and specific causes 





2. 2 METHODS 
 
We followed the Preferred Reporting Items for the Systematic Reviews and Meta-analysis 
Protocols (PRISMA-P) 2015 guideline (additional file1) (10). The protocol of this study is 
registered in PROSPERO with registration number: CRD42019141933. 
We searched observational studies reporting on morbidity and mortality in the antiretroviral 
therapy (ART) era in Sub-Saharan Africa. 
2.2.1 Eligibility criteria 
 
Inclusion criteria: 
. Studies reporting on morbidity and mortality in the antiretroviral era in Sub-Saharan 
Africa. 
. Studies conducted in the period of 2008 to 2018. 
. Studies reporting on adult males or females aged 18 years or older. 
. Peer-reviewed English language publications  
. Observational studies conducted in Sub-Saharan Africa. 
 
           Exclusion Criteria: 
           . Studies reporting on morbidity or mortality in HIV-uninfected patients.  
           . Studies reporting on adult males or females under the age of 18 years 
 
2.2.2 Search Strategy for identifying relevant studies 
To identify relevant studies, we searched in the following database: Google Scholar, Pub Med, 
CINAHL. Studies published in English from January 2008 to December 2018, conducted in 
Sub-Saharan Africa.  
The search strategy was based on a combination of relevant terms. 








Table 2.1: Search strategy in PubMed 
Search Search terms 
#1 (Morbidity OR Opportunistic infection 
related hiv) [MeSH Terms] 
#2 (Mortality OR Death) [MeSH Terms] 
#3 (ART OR Antiretroviral therapy) [MeSH 
Terms] 
#4 (Sub-Saharan Africa) [MeSH Terms] 
#5 #1 AND #2 AND #3 AND #4 
 
We adapted this search strategy for a possible extension to other databases and we also 
contacted experts in the field to identify additional eligible studies and we manually searched 
reference lists from relevant studies. 
2.2.3 Data collection, analysis and synthesis 
Two reviewers followed independently inclusion criteria for selecting studies, articles were 
identified and screened by their titles and abstracts for eligibility. The full texts of articles were 
retrieved. The process of literature selection and reasons for exclusion and inclusion were 
documented by a PRISMA (Preferred Reporting Items for Systematic Review and Meta-
Analysis) flow diagram (figure 1) (11). We used R software version 3.6.2. to analyze the data, 
we captured information into a spreadsheet about the most causes of hospitalization and death 
related to HIV in the antiretroviral treatment, Graphic displays (figure 2) was used to visually 
compare the prevalence of comorbidities across the study region. 
 
2. 3 RESULTS 
 
For the initial search, a total of 409 articles were retained, the number of studies was 
reduced to 12 after applying the exclusion criteria (Figure1). 























From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal. pmed1000097 for more information, visit www.prisma-statement.org 
 
2.3.1 Characteristics of included studies 
 
Out of 22 reviewed articles, 12 articles were eligible for data extraction (Table 2.2). All 12 
studies included were published between 2008 and 2018 in English and they were conducted 
in Sub-Saharan Africa.  Of these, three (14, 19, 20) were conducted in Nigeria, two (15, 24) 
Records identified through 
database searching 



























Additional records identified 
through other sources 
(n = 0) 
 
Records after duplicates removed 
(n = 388) 
Records screened 
(n = 388) 
Records excluded 
(n = 367) irrelevant 
Full-text articles assessed 
for eligibility 
(n = 22) 
Full-text articles excluded, with 
reasons 
(n =10) n:3 systematic review 
,n=6 no responding to research 
question, 1: outside sub 
Saharan Africa  
 
 
Sub Saharan Africa 
Studies included in 
qualitative synthesis 
(n = 12) 
42 
 
were conducted in Uganda, three were conducted in South Africa (21, 23,25), one in Gabon 
(18), one in Ethiopia (17), one in Ghana (16), and one in Burkina Faso (22).  The total sample 
size of 12 studies was 14619 participants, predominantly female.  According to the study 
designs of the included studies, we noticed seven retrospective chart /cohort studies 
(14,16,18,19,20,21,22), three prospective studies (15,24,25), two cross-sectional study (17, 
23). All included studies were aimed at assessing either cause of death or the most frequent 
diagnoses among HIV patients during the antiretroviral therapy era. In all included studies the 
first commonest cause of hospitalization was tuberculosis (14, 15,17,18,19,20,21,22,23,24) 
except in one (16) and the most cause of death  was tuberculosis in all the included studies 
(14,15,16,18,19,20,21,23,24 ) except in two (17,22,). We summarised the characteristics of all 
included studies in Table 2, and from this list, we extracted data related to the causes of 
hospitalization and death in the modern ART era in Sub Saharan Africa. Most of the articles 
reported on death than the hospitalization, and tuberculosis was the most disease reported 
(figure1). 
A total of 398 studies were excluded as they did not meet the inclusion criteria, of those 10 
underwent a full manuscript review and were found to have no valuable data for the following 
reasons:  Three systematic reviews ( 27,28,30),  1 article outside of Sub-Saharan Africa (32), 




Table 2.2. Characteristics of the included studies 
TB: Tuberculosis, CCM: cryptococcal meningitis, AT: ARV toxicity, CD: Chronic diarrhoea, OM: Opportunistic malignancies, NHRI: non-HIV 






































chart review  
Cause of hospitalization: TB (119,33.6%) ,  
cryptococcal meningitis (CCM) (31,8.8%) ,  
septicaemia (13,16.4%) ,  ARV toxicities 
(AT) (41,11.6%) ,  chronic diarrhoea (CD) 
(23,6.5%),  opportunistic malignancies 
(OM) (17,4.8%) , other infections (15, 
4.2%),  AIDS-demented complex (ADC) 
(4,1.1%) ,  non HIV related illness (NHRI) 
(32,9%),  no specified diagnosis (NSD) 
(14,4%)  
Among patients who died:  TB (37, 30.1%), 
CCM (16, 13.0%), Septicaemia (21, 
Findings illustrate the 
need for early 










17.1%), AT (4, 3.3%), CD (10, 8.1%), OM 
(12, 9.8%), Other infection (8, 6.5%), ADC 













causes of hospitalization: TB (37, 18%), 
CCM (22, 11%), 
Zidovudine (AZT) - with anaemia (19, 
10%), Sepsis (10, 5%) and Kaposi’s 
sarcoma (KS) (10, 5%). 
42 patients (21%) died:  TB (10,24%), 
CCM (8,19%), Sepsis (5,12%),  
undiagnosed neurological syndromes 









and treatment for 
opportunistic diseases 
and early ART 
initiation. Tenofovir-
based regimens, unless 
contraindicated should 
be scaled up to replace 






















Causes of hospitalization: Anaemia (76, 
34.2%), Toxoplasmosis: 65(29.3%), 
Pneumonia: (57, 25.7%), TB (45, 20.3%), 
HIV wasting syndrome: 44(19.8 %,), 
Gastroenteritis (GE) (28, 12.6%)   
Causes of death: TB (77, 34.7%), Anaemia 
(67, 30.2%), Cerebral toxoplasmosis (CT) 
(61, 27.5%), Pneumonia (51, 23.0%), GE 
(23, 10.4%) 
 
 In-patient mortality 
rate among HIV-
infected adults 
admitted to the KBTH 
(Korle-Bu Teaching 
hospital) is high. Most 
patients not receiving 
ART. Earlier initiation 
of ART may lower the 
risk of opportunistic 
infections (OI) and 
HIV mortality rates. 
High index of 
suspicion and 
initiation of empiric 
treatment for TB may 













Most common opportunistic infections: 
pulmonary tuberculosis (PTB) (118, 18%), 
severe Community-acquired pneumonia 
(SCAP) (107, 16.3%) and oral candidiasis 
The overall prevalence 











(OC) (103, 15.6%). The Main causes of 
death: bacterial meningitis (BM) (16, 
28.6%), PTB (13, 23.8%), SCAP (13, 
23.8%). 
Significant level of 
AIDS defining illness 
was noticed. 
WHO stage II–IV, 
CD4 level, ART 
adherence and 
haemoglobin level 




proper diagnosis and 
















Hospitalizations:  TB (114, 24.89%), herpes 
zoster (HZ) (73, 15.94%), CT (65, 14.19%), 
OC (65, 14.19%), and severe pneumonia 
(SP) (43, 9.39%), CM (2, 0.44%) and 
pneumocystosis (1, 0.21%), KS (9, 1.96%) 
Prevalence of 
opportunistic diseases 
























Causes of hospitalization :  TB (16,29.1%),  
sepsis (6, 7.3%), chronic diarrhoea 
(6,7.3%), KS(1, 1.8%), CT (1,1.8%),viral 
meningoencephalitis (VME) (1,1.8%), 
CCM (1,1.8%), herpes zoster (1,1.8%), AT 
(10, 18.1%), renal failure (RF) (2,3.6%), 
hypertensive heart failure (HHF) (2,3.6%) 
Causes of death: TB (7, 36.9%), sepsis (4, 
21.1%), KS (1, 5.3%), VME (1, 5.3%) 
CCM (1, 5.3%), RF (1,5.3%) SP (1, 5.3%), 
Acute bacterial meningitis (ABM) (1, 
5.3%). 
In current ART era, 
late presentation and 
TB continue to fuel 
HIV/AIDS, with 
emerging challenges 
due to ART-related 
complications 
Gyuse et, al 
2010, 
Nigeria 
350 61 35.4 Introducti











Causes of death: TB (24.0%), followed by 
sepsis and septicaemia (13.0%), meningitis, 
encephalitis and anaemia (11.0%), 
respiratory diseases (RD) (5%), hepatitis 
(2%), gastrointestinal disease (GID) (3%), 
and RF (3%). 
HIV/AIDS is a major 





,et al 2009,  
South 
Africa 










of mortality  
Retrospective 
cohort study 
Most common causes of death: 
TB(47,44.3%) and diarrhoeal diseases 
(DD) (26,24.5%), meningitis (5,4.7%), 
hepatic failure (HF) (3,2.83%), 
opportunistic malignancies (OM) (KS, 
prostate, cervix, bladder, endometrium) 
(7,6.59%), Pneumonia 
(2,1.89%),septicaemia (4,3.77%), HIV 
encephalopathy (HE) (1,0.94%), Diabetic 
ketoacidosis (DKA) (1,0.94%), RF 
(1,0.94%) 
Early HIV diagnosis, 
increased access to 























AIDS (64%) and non-AIDS related (36%).  
Causes of death: wasting (113, 26.9%), TB 
(67,16%), oesophageal /pulmonary 
candidiasis (O/PC) (22,5.2%), chronic 
diarrhoea (CD) (17,4.1%), Toxoplasmosis 
(16,3.8%), Cryptococcosis (7,1.7%), 
encephalopathy /dementia 7(1.7%), 
pneumocystosis (PC) (6,1.4%), OM (CC 
and KS) (5,1.2%), Leishmaniasis (5,1.2%), 
BP (4,1.0%), cytomegalovirus disease 
Testing patients for 
HIV and starting ART 
earlier to reduce the 




on ART (CVD) (1,0.2%), anaemia (22,5.2%), 
septicaemia (13,3.1%), respiratory disease 
(16,3.8%), AT (16,3.8%), metabolic 
disease (MD) (13,3.1%), myocardiopathy 
(MP) (14,3.3%), BM (4,1.0%), high blood 
pressure (HBP) (4,1.0%), depression 






















Most cause of hospitalization: TB (238, 
40.7%), Bacterial infection (100, 17.1%), 
AIDS other than TB (64,10.9%). Major 
organ dysfunction (59, 10.1%), other 
diagnosis (35, 6.0%), Venous 
thromboembolis (VTE) (1, 5.3%), Drug 
related (24, 4.1%), non-communicable 
diseases (NCDs) (22, 3.8%), psychiatric (9, 
1.5%), None diagnosed (3, 0.5%). 
Most causes of death: TB (37.2%) and other 
AIDS- (24.4%) 
HIV is still accounting 
for nearly two-thirds of 
medical admissions 






Moore et al., 
2011, 
Uganda 











Most common condition TB (21% of 
deaths), Candida disease (CD) (15%). 
cryptococcal disease (CCD) 
(12%), Pneumocystis jiroveci pneumonia 




were associated with 
mortality while on 
ART  
Mzileni et al 
2008, South 
Africa 








Causes of death: TB (42, 20.5%), CD (25, 
12.2%), CCM (18, 8.8%), bacterial 
pneumonia/pneumocystis pneumonia 
(BP/PCP) (12, 5.8%), KS and lymphoma 




expansion of earlier 





Figure 2.2: Prevalence of articles  
This graph reports the prevalence of articles that described the causes of death and of 
hospitalization. Some articles reported both and others reported either hospitalization or death, 
6 articles reported both causes of death and hospitalization, 5 articles reported causes of death 





























0 25 50 75











Table 2.3: Prevalence of the reason of hospitalization 
Diagnosis  min  IQR  Max 
     Q1 Q2  Q3   Q4 
Tuberculosis 18.0 19.1 24.9 31.4 40.7 
Cryptoccocal 
meningitis 1.8  5.3  8.8 9.9 11.0 
Septicaemia 16.4 16.4 16.4 16.4 16.4 
ARV_toxicities 4.1 8.5 10.8 13.2 18.1 
Gastroenteritis 6.5 8.7 10.9 11.8 12.6 
Malignancies 1.8 1.9 3.4 4.8 5.0 
Others 4.2 5.9 7.6 9.2 10.9 
No_diagnosed 4.0 4.0 4.0 4.0 4.0 
Toxoplasmosis 1.8 8.0 14.2 21.7 29.3 
Sepsis 5.0 5.6 6.2 6.7 7.3 
Cahexia 19.8 19.8 19.8 19.8 19.8 
Herpes 1.8 5.3 8.9 12.4 15.9 
Pneumocystosis 0.2 0.2 0.2 0.2 0.2 
Meningitis 1.8 1.8 1.8 1.8 1.8 
Pneumonia 16.3 18.7 21.0 23.3 25.7 
Anaemia 10.0 16.1 22.1 28.2 34.2 
Renal failure 3.6 3.6 3.6 3.6 3.6 
Non communicable 
disease  3.6 5.0 6.3 7.7 9.1 
Psychiatric 1.1 1.2 1.3 1.4 1.5 
Candidiasis 14.2 14.5 14.9 15.2 15.6 





In this table above tuberculosis holds the leading reason of hospitalization with 40.7% 
followed by anaemia with 34.2% and toxoplasmosis with 29.3%. Non communicable disease 
had been also noticed with 9.1%. 
 
Table 2.4: Prevalence of the cause of death 
Diagnosis   min  IQR  Max 
     Q1  Q2  Q3  Q4 
Tuberculosis  16.0 22.4 24.0 35.8 44.3 
Cryptoccocal 
meningitis 0.4 3.5 8.8 12.0 13.0 
Septicaemia 3.1 3.6 8.4 14.0 17.1 
ARV_toxicities 3.3 3.4 3.5 3.7 3.8 
Gastroenteritis 4.1 7.1 9.2 13.9 24.5 
Malignancies 1.2 5.5 6.3 7.9 9.8 
Others 6.5 11.0 15.4 19.9 24.4 
no_diagnosed 4.0 9.0 14.0 19.0 24.0 
Toxoplasmosis 1.7 8.2 14.6 21.1 27.5 
Sepsis 13.0 17.0 21.0 21.1 21.1 
Pneumocystosis 1.4 1.4 1.4 1.4 1.4 
Meningitis 1.0 4.7 5.3 11.0 28.6 
Pneumonia 1.0 3.6 5.8 8.7 23.0 
Anaemia 5.2 8.1 11.0 20.6 30.2 
Hepatitis 2.0 2.2 2.5 2.7 2.9 
Liver failure 2.8 2.8 2.8 2.8 2.8 
Renal failure 0.9 2.0 3.0 4.2 5.3 
Non communicable 
disease 1.4 2.1 2.8 5.1 7.4 
Psychiatric 0.7 1.1 1.5 2.0 2.4 
Candidiasis 5.2 7.7 10.1 12.6 15.0 
      
IQR: Interquartile range, Q2: Median 
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Regarding the table above, tuberculosis is the leading cause of death with 44.3%, respectively 




The objective of this study was to identify the causes of hospitalization and causes of death 
among HIV patients in the ART era in Sub-Saharan Africa. The causes reported were 
opportunistic infections, opportunistic malignancies, and non-AIDS related. Among 
opportunistic infections, in most of the included studies, tuberculosis was the commonest 
leading cause of hospitalization and death among people living with HIV. It accounted for 
between 18-40.7% (table2.3) of hospitalization and 16-44.3% (table2.4) of death. The 
prevalence of death reported due to tuberculosis was higher than what had been reported in 
Thailand (38). This may be a consequence of many countries of Sub Saharan Africa, not having 
well developed medical analysis laboratory yet, therefore late diagnosis of tuberculosis could 
imply the increased rate of morbidity and mortality. Non-expanding access and late initiation 
of antiretroviral therapy and anti-tuberculosis treatment in some countries in Sub-Saharan 
Africa could also increase the burden of the disease.  
 
Studies conducted in Rio de Janeiro; Brazil estimated 80% of reduction of tuberculosis 
incidence for HIV infected adults associated with the use of antiretroviral therapy (37). Many 
patients in Sub Saharan Africa arrived at the hospital at the later stage of disease with the rate 
of CD4 ≤ 200/cells/mm3, many patients do not have information on disease because of lack of 
counselling and testing services in the region. 
If patients start ART at the higher baseline CD4 count, there is potential to decrease morbidity 
and mortality (39). 
Of the included studies, one reported from Ghana did not find tuberculosis as the first cause of 
hospitalization in Sub-Saharan Africa, it reported anaemia as the first cause of hospitalization 
(16). The included studies accounted for 34.2% of hospitalization(table2.3) and 30.2% of death 
(table2.4) due to anaemia. Similarly, in America, another study among HIV infected African 
women found almost the same result (47). Anaemia is a known independent risk factor for 
death among HIV/AIDS patients. It has been reported that 59% of patients who suffer from 
anaemia are likely to die even if other opportunistic infections associated with it are treated 
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appropriately (46). Anaemia is known to be multifactorial, several factors like poor nutrition, 
malaria, hookworm infection and other infections have been reported among its causes (48).  
Other studies showed a relation between the prevalence of anaemia and HIV (40, 41). This may 
be a result of late initiation of ART. A Study in South Africa showed that early initiation of 
ART resolved 66% of anaemia in HIV positive patients after just one year of treatment (45). 
Two of the included studies in Burkina Faso, (22) and in Ethiopia, (17) did not find tuberculosis 
as the first cause of death, they found respectively wasting syndrome and bacterial meningitis. 
Similarly, out of the included studies, other studies did not find tuberculosis as the first leading 
cause of hospitalization and of death, in Europe, precisely in French Guyana, they reported that 
among AIDS-related deaths the most frequent diseases were histoplasmosis and toxoplasmosis 
(36). In Asia precisely in Taiwan, they reported that the first HIV-associated opportunistic 
infections were oesophageal candidiasis (43). 
 
Opportunistic malignancies accounted between 1.8%-5% of hospitalization (table2.3) and 
1.2%-9.8% of death (table2.4) in our included studies.  It was noticed that Kaposi Sarcoma was 
the most reported (14, 15, 24, 25) as causes of hospitalization and death among HIV patients. 
Lack of detecting early neoplasm through screening may imply the increase of the disease in 
Sub-Saharan Africa because many medical laboratories in Sub-Saharan Africa do not have 
devices and laboratories required to support the screening. 
Many people initiate ART while Kaposi sarcoma is already at advanced stages (44).  Similarly, 
in India Kaposi Sarcoma had been reported as the most opportunistic malignancy between 2% 
-5 % (13). 
 
Among non-AIDS related, in some of our included studies, ARV toxicities were shown to 
cause morbidity and mortality (14), (19), (15). The prevalence was almost the same in the three 
studies. To reduce morbidity and mortality, counselling about the adverse effects of 
antiretroviral drugs and aggressive monitoring of patients must be conducted before and after 
initiation to the antiretroviral therapy. Other non-AIDS related conditions like non-
communicable disease, psychiatric, had been reported on in some of our included studies (14, 
21, 22, 23). A better knowledge of the commonest comorbidities is very important to improve 
health promotion, prevention and care among HIV patients. Poverty, limited access to ART, 
malnutrition and interruption of supply at the program level had been found to be among the 






In conclusion, tuberculosis was the first commonest cause of hospitalization and death in Sub-
Saharan Africa according to the included studies, this was followed by other infectious 
diseases, opportunistic malignancies, and other non-AIDS related. To reduce morbidity and 
mortality in the ART era, all the different causes of hospitalization and causes of death must 
be attended to. 
 
2.6 RECOMMENDATION FOR FUTURE RESEARCH 
 
According to the findings, tuberculosis is the leading cause of hospitalization and the major 
killer of people living with HIV in Sub-Saharan Africa. 
We recommend early HIV diagnosis and initiation of ART. Additionally, we suggest 
strengthening of infrastructure for screening for tuberculosis, early initiation and increased 
access to ART, and to conduct research on the other opportunistic infections which always 
accompany tuberculosis, and non-communicable diseases. 
 
2.7 STRENGTHS AND LIMITATIONS 
The strength of this study is the relevant articles finding reported on the morbidity and mortality 
in the antiretroviral Era in Sub Saharan Africa. There are no limitations in this study. 
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CHAPTER 3: A CHART REVIEW 
 
This retrospective chart review aimed at identifying the determinants of morbidity and 
mortality in the modern antiretroviral treatment in South Africa. It is addressing objective 2 of 
the study. The results of this study will help to strengthen and influence policy and guide future 
research in antiretroviral treatment era. We present the chapter in the form of manuscripts 
entitled: ‘Morbidity and mortality in the modern antiretroviral treatment era in a tertiary 
teaching hospital in Durban, South Africa.’ 
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Introduction: Human immunodeficiency virus /acquired immune deficiency syndrome 
(HIV/AIDS) is a public health concern in South Africa.  This study aimed at identifying the 
determinants of morbidity and mortality in the era of modern antiretroviral treatment (ART). 
Methodology: A retrospective study was conducted; data were obtained from medical records 
of all HIV infected patients admitted to King Edward medical wards from January to December 
2018. This included demographic profile, clinical attributes and laboratory records. Data were 
analysed using R software where descriptive and inferential statistics were presented. That is, 
five numbers summaries, box plot, Chi square, all fisher exact test and t test or rank some test 
Results: A total of 577 (50.6%) females and 564 (49.4%) males aged 12 years old and older 
infected by HIV were included in the study. The mean age of all the patients was 39.6±12.2, 
506 (44.3%) patients had CD4 less than 200 cells /mm3 and 273 (23.9%) had VL ˃ 1000 
copies/ml. Association between CD4 cell count and Viral load (p˂ 0.05) was found. Male 
gender [OR 1.39(1.07-1.8) p=0.015], Age [OR1.02 (1.01-1.03) p˂ 0.001], CD4 <200 
cells/mm3 [OR 2.14(1.37-3.45) p=0.001], VL ˃ 1000 copies/ml [OR 1.93(1.08-3.63) p=0.032] 
were associated with mortality in our cohort.  Tuberculosis (TB) was the most common 
diagnosis on admission and the leading cause of death which accounted for 257 (22.5%) and 
73 (24.3%) respectively, followed by kidney disease with 83 (7.2%) for admission and 38(12.6) 
for death. Only 70% of patients had been reported to be on ART. 
Conclusion: Despite the modern antiretroviral treatment which is free, available to everyone 
and with fewer toxicities, HIV infected patients are still hospitalized with HIV-related 
complications and are also dying of AIDS. Most of the patients have been admitted with a low 
CD4 cell count, an indication of delayed initiation of treatment or not properly adhering to 
treatment. This was found to be associated with a high prevalence of TB, other opportunistic 
infections and non-communicable disease. Hence, the need for raising the awareness of early 
appropriate treatment, prevention of opportunistic infection and tackling non-communicable 
disease related to HIV. Also, these findings illustrate the need to investigate the reason for 
starting treatment late.  








Worldwide, Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency 
Syndrome (AIDS) pandemic is a challenging public health concern (1). South Africa bears the 
highest number of people living with HIV/AIDS (2). Statistics showed that in 2012 
approximately 6.4 million HIV infected people living in South Africa were 17% of the global 
burden of infection (3). In 2018 an estimation of 7.7 million people was living with HIV in 
South Africa (4). In the same year, 240,000 new HIV infections appeared, and 71,000 South 
Africans died from AIDS-related illnesses (5). South Africa implemented the National 
HIV/AIDS and Sexually Transmitted Infections (STI) National Strategic Plan (NSP) to tackle 
the HIV/AIDS epidemic. The primary objectives of this plan were to reduce HIV incidence by 
50% and to expand the availability and access to ART to 80% of all HIV infected patients in 
the country (6).  
The target of the Joint United Nations Programme on HIV/AIDS (UNAIDS) is to have 90% of 
all people tested for HIV, 90% treated, 90% virologically suppressed by 2020 and to end HIV 
infection (7). Early access to antiretroviral therapy (ART) to all people living with HIV 
regardless of CD4 count improve life expectancy (7). Due to the modern antiretroviral therapy 
which has enhanced the survival of HIV patients (8), HIV infection is no longer a fatal illness 
but a chronic disease which is now manageable (9). The antiretroviral therapy (ART) 
suppresses viral replication, restores immune function, reduces HIV associated morbidity and 
mortality (10). 
Despite these gains, 8-26% of African patients die in the first year of initiating ART, with most 
deaths occurring in the first three months (11). Mortality is attributed to late initiation of ART 
when patients have advanced disease with increased risk of opportunistic infections and 
immune reconstitution inflammatory syndrome (12). The systematic review has shown the 
causes of morbidity and mortality in Sub-Saharan Africa in the ART era as tuberculosis, 
anaemia, meningitis, toxoplasmosis, gastroenteritis, pneumonia. Currently, antiretroviral 
treatment is freely available and modern, there is a fixed-dose combination, drugs are less toxic 
unlike in the past where most of the drugs were toxic with multiple treatment-related 
complications (8). Based on advances made in treatment, AIDS-defining illnesses related 
should no longer be observed, however up until today HIV infected patients still suffer and die 
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from AIDS. Many barriers to adherence to ART had been revealed by several studies, among 
them socio economic factors (such as poverty, food insecurity, unemployment and transport 
costs) education, cultural, political factors, stigma, discrimination, lack of social support (13, 





We conducted a retrospective study of HIV infected patients who had been admitted in the 
medical ward at King Edward hospital, Durban, South Africa. 
Study population 
All records of patients admitted to the medical wards from January to December 2018 were 
reviewed. Those included in the study were all HIV infected patients aged 12 years old and 
older who had been hospitalized in the medical wards at King Edward hospital during the study 
period. Non-HIV patients and children were excluded. 
 
Data extraction 
Data extracted from medical records included socio-demographics, clinical parameters, 
admission date, discharged date, deceased date, causes of death, causes of hospitalization, 
laboratory data (CD4 cell count, RNA viral load, based on the HIV test) and ART. The reasons 
for admission and causes of death were based on the final diagnostic on discharge. The final 
diagnostic on discharge was obtained after the patients had carried out laboratory examinations. 
It was based on similar standardized terminology. 
STATISTICAL ANALYSIS 
R statistical computing software version 3.6.2. was used for data analysis. Tables and graphical 
displays were used to present the results. In addition, the association between the covariates 
was tested either with the Chi-Square test, Kruskal Wallis or Wilcoxon rank-sum test 
depending on the type of variables. A p-value < 0.05 was used as a benchmark for determining 
the level of statistical significance.  
 ETHICAL APPROVAL 
We obtained full ethical approval from the Biomedical Research and Ethics Council  
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Four thousand (4000) records of patients of 12 years and older admitted to the medical wards 
at King Edward hospital from January to December 2018 were examined. This study included 
1 141 patients diagnosed or known HIV positive. Out of the 1 141 patients, 564 (49.4%) were 
males and 577 (50.6%) were females. The mean age for the entire cohort was 39.7±12.1, with 
a range of 12 to 92, 506 (44.3%) patients had CD4 count <200 cells /mm3, 253 (22.2%) patients 
had a viral load more than 1000 copies/ml.  Among the included patients 301 (26.3%) died, 
while 840 (73.6%) were discharged home alive (table3.1). Age, male gender, CD4 cell and 
Viral load were associated with mortality (p˂ 0.05) (table3.2). Association between CD4 cell 
count and viral load was found (table3.3). Tuberculosis was the most common diagnosis 
reported at admission and accounted for 257 (22.5%) of the admissions, followed by kidney 
disease 83 (7.2%), anaemia 75 (6.6%), cryptococcal meningitis 62 (5.4%). Tuberculosis was 
also the number one cause of death with 73 (24.3%) followed by acute or chronic kidney 
disease 38 (12.6%), Pneumonia 19 (6.3%). Other conditions that were responsible for 
admission 166 (14.5%) and death 43 (14.3%) are shown in table3.4 and table3.5, respectively. 
There was no significant difference in the duration of hospital stay between males and females 
(fig3.1).  It was noticed that 70% of patients were reported to be on ART, among them, 53.1% 

















Table 3.1. Comparison of HIV patients in medical wards at King Edward hospital by 









Gender   0.014  
Male (Ref) 397 (47.3%) 167(55.5%)  564(49.4%) 
Age   0.007  
Mean±SD 38.9±11.7 41.8±13.1  39.7±12.1 
CD4(cells /mm3)   0.001  
<200 363 (43.2%) 143 (47.5%)  506 (44.3%) 
200-<350 126 (15.0%) 34 (11.3%)  160 (14.0%) 
350-<500 100 (11.9%) 20 (6.6%)  120 (10.5%) 
500+ 141 (16.8%) 26 (8.6%)  167 (14.6%) 
Missing 110 (13.1%) 78 (25.9%)  188 (16.5%) 
Length hospital 
stay(days) 
  0.003  
Mean±SD 9.46±9.43 8.65±10.5  9.25±9.72 
Viral load 
(copies/ml) 
  0.049  
<50 104 (12.4%) 16 (5.3%)  120 (10.5%) 
50-<1000 94 (11.2%) 17 (5.6%)  111 (9.7%) 
1000+ 195 (23.2%) 58 (19.3%)  253 (22.2%) 
Missing 447 (53.2%) 210 (69.8%)  657 (57.6%) 






Table 3.2. Factors associated with Mortality among HIV infected patients admitted at 
King Edward hospital  
Explanatory OR(Univariable) OR(Multivariable) 
Gender:  
Male (Ref) 1.39 (1.07-1.81, p=0.015) 1.12 (0.68-1.84, p=0.647) 
CD4 (cells /mm3) 
<200  2.14 (1.37-3.45, p=0.001) 4.45 (1.96-11.62, p=0.001) 
200- <350 1.46 (0.83-2.59, p=0.186) 2.41 (0.87-7.16, p=0.097) 
350-<500 1.08 (0.57-2.04, p=0.803) 1.00 (0.24-3.64, p=0.999) 
Age(years) 
20-40  1.69 (0.74-4.57, p=0.250) 2.67 (0.40-54.12, p=0.389) 
40-60  1.88 (0.82-5.09, p=0.169) 2.93 (0.29-71.84, p=0.413) 
60+  3.94 (1.55-11.48, p=0.007) 8.02 (0.38-304.00, p=0.204) 
Duration(weeks) 
1-2  0.60 (0.42-0.85, p=0.005) 0.49 (0.20-1.11, p=0.095) 
2-3  0.70 (0.43-1.11, p=0.142) 0.25 (0.06-0.89, p=0.038) 
3 0.80 (0.52-1.21, p=0.308) 0.43 (0.05-2.79, p=0.389) 
Viral load (copies/ml) 
50-1000 1.18 (0.56-2.48, p=0.667) 1.08 (0.48-2.44, p=0.857) 
























Gender    0.609  
Male (Ref) 58 (48.3%) 49 (44.1%) 
126 
(49.8%) 
 564 (49.4%) 
Age    0.675  
Mean±SD 39.4±11.4 39.5±10.5 39.1±12.5  39.7±12.1 
CD4(cells/mm3)    < 0.001  
<200 39 (32.5%) 47 (42.3%) 
165 
(65.2%) 
 506 (44.3%) 
200-<350 11 (9.2%) 25 (22.5%) 38 (15.0%)  160 (14.0%) 
350-<500 17 (14.2%) 19 (17.1%) 18 (7.1%)  120 (10.5%) 
500+ 51 (42.5%) 19 (17.1%) 28 (11.1%)  167 (14.6%) 




   0.909  
Mean±SD 10.0±9.13 9.41±8.36 10.4±10.3  9.25±9.72 







 840 (73.6%) 














Table 3.4. Reasons for admissions among HIV patients in medical wards at King 
Edward hospital 
Diagnosis Frequency Percentage 
Tuberculosis 257 22.5% 
Kidney disease 83 7.2% 
Anaemia 75 6.6% 
Cryptococcal meningitis 62 5.4% 
Pneumonia 56 4.9% 
Gastroenteritis 42 3.7% 
Parasuicide 35 3.1% 
Lymphoma 32 2.8% 
Sepsis 31 2.7% 
Congestive cardiac failure 29 2.5% 
Cerebrovascular accident 25 2.2% 
Unspecified meningitis 25 2.2% 
Liver failure 24 2.1% 
Bronchopneumonia 19 1.7% 
Viral meningitis 19 1.7% 
Hypertension 18 1.6% 
Psychiatric 14 1.2% 
Diabetic ketoacidosis 13 1.1% 
Diabetes mellitus 10 0.9% 
Headache 10 0.9% 
Deep vein thrombophlebitis 9 0.8% 
Epilepsy 9 0.8% 
Adult onset seizures 8 0.7% 
Asthma 8 0.7% 
Bronchiectasis 7 0.6% 
Heart failure 7 0.6% 
Kaposi's sarcoma 7 0.6% 
Pneumocystis pneumonia 7 0.6% 
Drug-induced liver injury 6 0.5% 
Nephrotic syndrome 6 0.5% 
Thrombocytopenia 6 0.5% 
Cholelithiasis 5 0.4% 
Gastritis 5 0.4% 
Hepatocellular carcinoma 3 0.3% 
Toxoplasmosis 3 0.3% 
Other medical illnesses non HIV related 166 14.5% 






Table 3.5. Causes of death among HIV patients in medical wards at King Edward 
hospital 
 
Diagnosis Frequency Percentage 
Tuberculosis 73 24.3% 
kidney disease 38 12.6% 
Pneumonia 19 6.3% 
Liver failure 14 4.7% 
Anaemia 13 4.3% 
Congestive cardiac 
failure 13 4.3% 
Gastroenteritis 12 4.0% 
Cryptococcal meningitis 10 3.3% 
Lymphoma 10 3.3% 
Sepsis 10 3.3% 
Bronchopneumonia 9 3.0% 
Unspecified meningitis 9 3.0% 
Cerebrovascular 
accident 8 2.7% 
Viral meningitis 8 2.7% 
Kaposi's sarcoma 6 2.0% 
Diabetic ketoacidosis 3 1.0% 
Hepatocellular 
carcinoma 3 1.0% 
Other medical illnesses 
non-HIV related. 43 14.3% 









Figure 3.1. Length of hospital stay 
 
The p-values are more than 5% implying that there was no significant difference in the duration 
of stay between males and females. This applies to both the duration of stay before discharged 
or demising. 

























This study aimed to identify the determinants of morbidity and mortality among HIV infected 
patients in the modern era of antiretroviral treatment (ART) at King Edward hospital from 
January to December 2018.  
In this study tuberculosis was reported to be the most cause of hospitalization and of death 
accounting with 22.5% and 24.3%, respectively (table3.4, table3.5). Similarly, in Uganda, a 
study reported 18% of admissions and 24% of death due to tuberculosis (16). Other studies 
conducted in Nigeria (17), in Gabon (18) and in South Africa (41) had similar findings. 
This may be as a result of lack of or poor TB preventative strategies, inadequate HIV 
counselling and testing services, also delays in referral and ART initiation are all potential 
reasons for late consultation and increase of TB.  Other issues include, the poor infection 
control measures in most public spaces, lack of active case finding (ACF) and contact tracing. 
A study conducted in the Ivory coast showed that access to antiretroviral therapy alone or early 
antiretroviral treatment with isoniazid preventive therapy (IPT) respectively, decrease the risk 
of mortality among HIV patients (21). Another study conducted in Rio de Janeiro revealed that 
TB prevalence and mortality of HIV patients were significantly reduced by increasing TB 
screening and the implementation of IPT (22). 
In addition, as in majority (44.3%) of the patients included in this study, CD4 counts were ≤ 
200 cells /mm3 and VL ˃ 1000 copies/ml, that is a risk for developing an opportunistic 
infection. Other studies conducted in Gondar and India reported a high risk of developing 
opportunistic infection among this group (19, 20).  
 
Anaemia and cryptococcal meningitis were also frequently diagnosed during admission. 
Anaemia accounted for 6.6% of admission. This was less than what had been found in Ghana 
(23). In this study, iron deficiency, vitamin B12 deficiency, folate deficiency and side effect of 
zidovudine are suspected to induce anaemia. Many patients had been admitted at the late stage 
of their disease that implied a delay in their initiation to antiretroviral treatment. Anaemia is 
known to be a significant problem among patients with HIV infection (24). 
Even though anaemia can occur at any stage of HIV infection, its frequency and severity are 
positively correlated with progression of the disease (25). Providing an early antiretroviral 
treatment, in general, is known to decrease anaemia among HIV patients by inhibiting the 
progress of the diseases, however zidovudine an element of some antiretroviral treatment 
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regimens is identified as the commonest cause of drug-associated anaemia in low-income 
countries (26). A study conducted in Ethiopia showed that overall, ART exposure reduced 
anaemia prevalence among HIV patients (27). 
Cryptococcal meningitis accounted for 5.4% of admission among HIV patients included in this 
study. Similarly, the same findings were also found in Latvia (28) and in Uganda (35). This 
may result as most of the HIV patients included in this study had lack of information about 
preventive therapy among those with low CD4 cell counts. Some of the patients had delayed 
initiation to ART. Cryptococcal meningitis is an opportunistic infection which occurs in HIV 
patients in their late stage of disease (30). Screening of cryptococcal antigenemia among 
persons living with HIV can allow early identification of symptomatic cases and improve 
health outcomes. The early access to antiretroviral treatment had improved the immune system 
of many HIV patients so that they do not become vulnerable to infection with cryptococcus 
(29). Studies conducted in the United States (31) and in Thailand (32) showed how fluconazole 
prophylaxis reduced the incidence of cryptococcal disease among HIV patients. 
 
After tuberculosis, kidney disease (acute or chronic) was found as the second reason for 
admission and second causes of death. Among HIV infected patients admitted to King Edward, 
7.2% accounted for admission and 12.6% for death, which is comparable to what had been 
reported in Zambia (41). Renal failure in HIV infection is associated with increased morbidity 
and mortality (33). Patients who were admitted at the late stage of the disease and had low CD4 
less than 200 cells /mm3 that also contributed to renal impairment. A study reported that chronic 
renal failure usually occurs only in advanced disease and mostly in patients with a CD4 count 
of fewer than 200 cells / mm3 (34). The early access to antiretroviral treatment may improve 
impaired renal function among HIV patients (35). In the ART regimen, tenofovir (TDF) is the 
first-line treatment of HIV infection, however, it is associated with a higher risk of kidney 
disease (47). 
 
The other cause of death was pneumonia with 6.3% after kidney disease. A study conducted in 
Uganda found almost the same prevalence of pneumonia among HIV patients (36), however, 
another study conducted in Malawi (37) found a high prevalence of pneumonia than this study. 
According to the findings of this study, pneumonia might result because of lack of preventive 
therapy among HIV patients who had been admitted to the hospital and most of them starting 
late antiretroviral treatment. It had been found that ART is independently and statistically 
significantly associated with decreased mortality and morbidity in pneumonia patients (38). 
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Some patients were admitted at the hospital with acute symptoms, such as an acute respiratory 
failure, a study shows that it is a complication of pneumonia and it is associated with a high 
risk of death among HIV patients (39). 
 
Even though there were more women than men included, more men died while admitted to the 
hospital than women with (p˂ 0.05). This is comparable to that reported from another study 
conducted in Nigeria (40). In this study, male gender was admitted with lower CD4 cell counts 
and more severe opportunistic infection. Men may be presenting into care later than women 
with more advanced disease.  
Age, male gender, CD4 cell count less than 200 cells /mm3, HIV viral load more than 1000 
copies/ml were reported to be associated with mortality in patients. These findings indicate that 
patients who died during hospitalization were more likely to present with poor performance 
status and more advanced and severe disease. A study conducted in Ethiopia reported almost 
the same, they found CD4 count ≤ 200cells/mm3 as a prediction of mortality (43). This study 
found an association between CD4 cell count and HIV viral load (p˂ 0.05), low CD4 cell count 
implies high viral load, and this might result as most of the patients had been admitted in the 
advanced status of the disease. However, a study conducted in Europe had contrary findings 
(44). 
 3.5 CONCLUSION 
 
Regarding the modern era of ART, there have been many improvements. Currently, ART 
regimens are well tolerated with fewer associated severe adverse events that avoid disability or 
permanent damage compared with older regimens used in the past (45). Numbers of patients 
switching or discontinuing treatment have decreased, compared to a decade ago (46), 
Treatment is easier to take unlike in the past. Fixed-Dose Combination (FDC) using one pill a 
day as opposed to two doses of three to four drugs a day can be taken (42).  Despite this 
improvement in treatment, people living with HIV are still hospitalised and die of AIDS. This 
study found that many patients were admitted with a low CD4, an indication of advanced 
disease. Age, male gender, CD4 cell count less than 200 cells /mm3, HIV viral load more than 
1000 copies/ml were reported to be associated with mortality in patients. Tuberculosis remains 
the most common cause of morbidity in patients infected with HIV infection in South Africa. 
This study noticed that non-communicable disease such as kidney disease play a huge role in 
mortality among HIV patients admitted in South Africa. Not only opportunistic infection 
should be focused on, but the non-communicable disease also should be tackled to reduce 
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morbidity and mortality among HIV patients in South Africa.  Health care professionals should 
take measures to strengthen the early diagnosis, prevention and treatment of the common 
opportunistic infections by investing effort into the improvement of education, screening, 
initial diagnosis and treatment in the community. High mortality among men was associated with 
more advanced disease. 
3.6 LIMITATION OF THE STUDY 
 
As the study was retrospectively designed, some detailed clinical and laboratory (CD4 and viral 
load) variables were not available for some patients. There were missing variables such as ART 
treatment, viral load and CD4 count cell of some patients on some files.  
However, the missing data did not significantly affect the major outcomes of the study since 
the findings were comparable to those within and outside South Africa.  
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CHAPTER 4: SYNTHESIS: SUMMARY, CONCLUSION AND 
RECOMMENDATIONS. 
 
 This chapter presented a summary of the research findings, assess the strengths and 
limitations of the study. The conclusion, recommendations for improving existing services 




The main aim of this study was to identify the determinants of morbidity and mortality in the 
modern antiretroviral treatment (ART) era in South Africa.  
Many improvements have been observed in the modern ART era, such as fixed-dose 
combination, availability of free treatment, and fewer toxicities of drugs unlike in the past. 
Despite that, patients are still hospitalized and die of AIDS. According to UNAIDS, South 
Africa have the largest programme of antiretroviral treatment in the world (1). South Africa’s 
antiretroviral therapy services have expanded in keeping with the WHO changing guidelines 
(2). 
The systematic review conducted in Sub-Saharan Africa identified the research gap, suggested 
novel ideas for future research. The retrospective chart review gave an overview of the causes 
of death and admissions among HIV infected patients in the medical ward at King Edward 
Hospital in South Africa. There is a need for an early initiation to antiretroviral treatment and 
preventive therapy of AIDS. Tuberculosis remains the main commonest cause of 
hospitalization and death in Sub-Saharan Africa and in South Africa. The conclusion and 
recommendation drawn in this study will benefit the millions of HIV infected patients and 
health care professionals. 
 
4.2 KEY FINDINGS OF THE STUDY 
  
The research questions needed answers about the gaps in research on morbidity and mortality 
in the modern ART era in South Africa.  The Chart review study has shown that 43.3% of 
patients were admitted with a low CD4 cell count, an indication of advanced disease. Another 
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study conducted in South Africa found also the same (3). Age (60 years old and older), men 
gender, CD4 cell count less than 200 cells /mm3, Viral load more than 1000 copies/ml were 
reported to be associated with mortality inpatients. In Brazil, another study found age and male 
gender to be associated with mortality (4) and in Canada, CD4 cell count and Viral load were 
also associated with death (5). Tuberculosis was the commonest cause of admission and death 
in South Africa, similarly, other studies reported the same results (6, 7, 8). However, even 
though tuberculosis was the first commonest cause, it was always followed by other 
opportunistic infections and non-communicable diseases.  In this study, tuberculosis was 
followed by chronic kidney disease as the second cause of death and it was followed by 
anaemia as the second cause of admission. Therefore, to reduce morbidity and mortality among 
HIV infected patients, focus must be drawn to non-communicable diseases. On the other hand, 
the systematic review revealed some studies conducted in Sub-Saharan Africa that did not find 
tuberculosis as the first cause of death and admission among HIV patients. Two studies, one 
conducted in Burkina Faso (9) and another in Ethiopia (10) revealed respectively wasting 
syndrome and bacterial meningitis to be the first causes of death among people living with 
HIV. One study conducted in Ghana (11) reported anaemia to be the first cause of admission 
among HIV infected patients. This difference may be due to the burden of dual HIV/TB 
epidemic in South Africa (12). 
 
4.3 STRENGTHS OF THE STUDY 
 
The systematic review was based on studies carried out in Sub-Saharan Africa. The strength of 
the systematic review is its rigorous methodology. Relevant studies were identified by 
searching in Google Scholar, Pub Med and CINAHL.  A research strategy was performed based 
on a combination of relevant terms. Two reviewers screened abstracts and full-text articles 
following the inclusion and exclusion criteria as outlined in the protocol. The research team 
followed the Preferred Reporting Items for the Systematic Reviews and Meta-analysis 
Protocols (PRISMA-P) 2015 guideline (13). The process of literature selection and reasons for 
exclusion and inclusion were documented by a PRISMA (Preferred Reporting Items for 
Systematic Review and Meta-Analysis) flow diagram (14). In order to ensure eligibility of the 





The retrospective chart review used secondary data. The advantage of this is that the data is 
already available and accessible, this reduce the costs and save time during data collection. The 
sample size of 1 141 medical records of HIV infected patients attending the medical wards at 
King Edward hospital was used.  Those patients had been admitted to King Edward VIII, a 
tertiary teaching hospital, from January to December 2018. KwaZulu-Natal is known to have 
the highest prevalence of HIV infections in all provinces in South Africa, and it is the epicentre 
of the HIV epidemic (16).   The results of the chart review would impact and improve treatment 
of HIV patients, they would give a general overview of the morbidity and mortality in the 
modern ART era in South Africa. 
 
4.4 LIMITATIONS OF THE STUDY 
 
According to the systematic review, the objective was to identify the causes of morbidity and 
mortality in the ART era. Some of the selected articles were pertaining to only the causes of 
admission without mentioning the causes of death. 
With regards to the retrospective chart review, some limitations such as missing variables such 
as ART treatment, viral load and CD4 count cell of some HIV patients. Some files were 
illegible due to the handwriting of some physicians. On the other files, HIV status of some 




The study identified the determinants of morbidity and mortality among HIV patients in the 
modern ART era in Sub-Saharan Africa, and particularly in South Africa. Despite the recent 
improvement of modern antiretroviral treatment, HIV patients still face many challenges. Early 
access to antiretroviral treatment and public awareness may improve the life expectancy of 
HIV infected patients.    
Prevention of opportunistic infection (especially tuberculosis) and non-communicable disease 
remain important among HIV patients.  There is a need to prioritise defensive prophylaxis and 








2. Prevention of the main non-communicable disease which always accompany 
HIV/AIDS 
3.  Counselling and HIV test for all patients admitted in the medical ward at King 
Edward Hospital. 
 
4. Monitoring renal function before initiating and while using ART in HIV patients. 
 
5. We suggest mobile HIV counselling and testing, community-based door to door HIV 
counselling and testing with linkage to care will serve the dual purpose of early 
diagnosis of HIV and early ART initiation thus. 
 
6. Preventive therapy of all opportunistic infections among HIV patients. 
 
7.  Early antiretroviral treatment to all HIV patients  
 
8. Educate Patients not to use toxic herbs which can damage their kidneys  
 
9. Test routinely, the CD4 and Viral load for each HIV patient at admission. 
 
4.7 FUTURE STUDIES 
1. Conduct the same study in the rural area where people do not have more information 
about HIV/AIDS. 
2. Conduct a prospective study based on the association between non-communicable 
disease and HIV in the modern ART era.  
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